Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2024, Taysha’s Board of Directors granted Meredith Schultz, M.D., M.S., an option to purchase 257,700 shares of the Company’s common stock in connection with her employment as Taysha’s new Senior Vice President, Clinical Development and Medical Affairs. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to Ms. Schultz entering into employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at globenewswire.com